Louisiana House Bill HR86

Louisiana 2022 Regular Session

• Introduced: 4/25/22
• Passed: 4/26/22

Caption

Designates May 1-7, 2022, as Tardive Dyskinesia Awareness Week

Impact

The establishment of Tardive Dyskinesia Awareness Week is intended to enhance public knowledge and understanding of TD, which affects an estimated 600,000 Americans. With this resolution, the Louisiana legislature is taking a proactive step towards educating the medical community and the public about the potential long-term effects of antipsychotic medications. It encourages citizens to inform themselves about the disorder and the recent FDA-approved treatments that can aid in managing TD, thereby fostering better health outcomes for those affected.

Summary

House Resolution 86 designates the week of May 1-7, 2022, as Tardive Dyskinesia Awareness Week in Louisiana. The resolution aims to raise awareness of Tardive Dyskinesia (TD), a serious movement disorder that can develop due to the use of dopamine receptor blocking agents (DRBAs), commonly prescribed for various mental health and gastrointestinal disorders. The resolution highlights the importance of recognizing TD and the need for regular screening among patients treated with these medications, as many individuals affected by TD remain unrecognized and misdiagnosed.

Sentiment

Overall, the sentiment surrounding HR86 is positive, with emphasis on the importance of awareness and education in addressing mental health issues. Advocates for mental health have expressed support for the resolution as it aligns with broader efforts to reduce stigma and promote understanding of mental health conditions and their treatment options. The bill is seen as a necessary recognition of a condition that is often overlooked and under-discussed in public health conversations.

Contention

There are limited points of contention associated with HR86, as it mainly focuses on awareness rather than implementing specific regulatory changes or funding. However, discussions might arise regarding the adequacy of resources allocated towards educating healthcare providers about TD and ensuring that patients can access the newly approved treatments. Critics may also call for more comprehensive measures beyond awareness to truly address the challenges faced by patients with TD.